Effect of pemafibrate on lipid and bile acid metabolism in patients with fatty liver or primary biliary cholangitis

Effect of pemafibrate on lipid and bile acid metabolism in patients with fatty liver or primary biliary cholangitis - Effect of pemafibrate on lipid and bile acid metabolism in patients with fatty liver or primary biliary cholangitis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039125

Enrollment

Registered

2020-01-15

Start date

2020-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver, PBC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hypertriglycemia who have fatty liver or PBC

Exclusion criteria

Exclusion criteria: 1. severe liver dysfunction (C-P B or C) 2. moderate or severe renal dysfunction 3. gallstone 4. pregnant women

Design outcomes

Primary

Measure	Time frame
Hepatic fat evaluated by MRS in 6 months (fatty liver patients) Serum ALP levels in 6 months (PBC patients)	—

Countries

Japan

Contacts

Public ContactTatehiro Kagawa

Tokai University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine,

kagawa@tokai.ac.jp0463-93-1121

Outcome results